Rochester,NY 8/28/2009 11:25:46 PM
Adolor Corporation.,ADLR-lower estimated hospital costs on Phase 3 Clinical Trial Data for Use of ENTEREG
Adolor Corporation
Aug 20, 2009, Adolor Corporation and GlaxoSmithKline plc declared that an economic analysis of Phase 3 clinical trial data reported that the use of ENTEREG after bowel resection surgery lowered the amount of time patients spent in the hospital by one day, resulting in lower estimated hospital costs compared with placebo.
The results, published in the American Journal of Health-System Pharmacy, were based on a post-hoc pharmacoeconomic analysis of pooled data consisting of 1,409 patients who participated in four randomized, double-blind, placebo-controlled, Phase 3 efficacy studies of ENTEREG conducted in North America. Patients evaluated in the four Phase 3 trials received standardized accelerated care treatment -- removal of nasogastric tube before first postoperative dose, early ambulation, and early feeding.
About Stock Einstein
StockEinstein uses proprietary technologies coupled with years of experience to uncover stocks we feel have the greatest potential for breakout performance. We utilize not only software, but time tested criteria to uncover these potential winners. When these benchmarks are reached or exceeded, our subscribers are immediately notified.
This service is free and available only to subscribers. Scroll to the bottom of this page to signup for free stock alerts and visit our site.
Disclaimer: Full disclaimer at http://StockEinsteain.com/disclaimer.php
IMPORTANT: Never invest in any stock featured in any press release, email or website unless you can afford the loss of your entire investment. Stocks and particularly penny stocks have the possibility for dramatic gains, and also losses. Neither StockEinsteain, nor any of its affiliates are registered investment advisors or broker dealers.
